Biosimilars are defined as the follow-on versions of original biological medicines. These are separately developed after the patent protecting the original product has expired. Biosimilars are intended to have the same MOA as original biological drugs and are designed to treat the same diseases as the innovator’s product. They have many similarities, but are not identical to, the reference biopharmaceutical product.

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Top-vendor offerings

Assumptions

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

Biosimilars: Overview

Comparative analysis of biosimilars and generic small

molecules

Biosimilars market opportunities

Challenges for new entrants

Bio-betters

PART 05: Pipeline portfolio

PART 06: Market landscape

Market overview

Five forces analysis

PART 07: Market segmentation by application

Global blood disorders biosimilars market

Market overview

Global oncology biosimilars market

Global chronic and autoimmune diseases biosimilars

market

Global growth hormone deficiency biosimilars market

Global infectious diseases biosimilars market

Others

PART 08: Market segmentation by end-user

Hospitals

Retail pharmacies

PART 09: Geographical segmentation

Global biosimilars market by geographical segmentation

2015-2020

Biosimilars market in EMEA

Biosimilars market in APAC

Biosimilars market in Americas

PART 10: Market drivers

Rise in number of patent expiries

Need for cost-effective treatment

Reimbursement benefits for biosimilars

Favorable government regulations

Promising pipeline

PART 11: Impact of drivers

PART 12: Market challenges

Physicians reluctance to prescribe biosimilars

Multiple manufacturing complexities

Risks related to drug failure

Limited availability of biosimilar products

Difficulties in patient recruitment for conducting clinical

trials

PART 13: Impact of drivers and challenges

PART 14: Market trends

Emergence of biosimilars

Outsourcing of biosimilar manufacturing activities

Need for high investment in R&D

High growth in the emerging markets

Rising number of strategic collaborations

PART 15: Vendor landscape

Competitive scenario

Sandoz

Hospira

Teva Pharmaceuticals

STADA

Biocon

Celltrion

Dr. Reddy's

Other prominent vendors

PART 16: Appendix

List of abbreviations

PART 17: Explore Technavio